Login / Signup
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients.
D Wang
C Zeng
B Xu
J-H Xu
J Wang
L-J Jiang
Q-X Wang
Chun-Rui Li
N Wang
Liang Huang
Y-C Zhang
Y Xiao
J-F Zhou
Published in:
Blood cancer journal (2020)
Keyphrases
</>
end stage renal disease
diffuse large b cell lymphoma
ejection fraction
newly diagnosed
chronic kidney disease
acute lymphoblastic leukemia
prognostic factors
multiple myeloma